Nebenwirkungen · Rxulti
RXULTI 0.25 mg film-coated tablets RXULTI 0.5 mg film-coated tablets RXULTI 1 mg film-coated tablets RXULTI 2 mg film-coated tablets RXULTI 3 mg film-coated tablets RXULTI 4 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-132071 · Präparat HOS-097184
Prolactin The incidence of blood prolactin increased was 0.9 % in the 2 mg to 4 mg brexpiprazole group compared to 0.5 % in the placebo group in short-term, controlled trials. Higher frequencies of prolactin increased (1.5 % versus 0.60 %) were observed in females compared to males in short-term trials. In addition, the frequencies of prolactin elevations > 1 × ULN in the 2 mg to 4 mg brexpiprazole group was 13.7 % in females versus 6.4 % in the placebo group and 11.1 % in males versus 10.3 % in the placebo group. See section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-12T14:38:00Z · SHA-256 d060cc667cc18af4e73efacd249c6f69ccb808c8be005b26cc608ba465837472 · Passage 025f7764a00ac1a4dd4b6588599552ebd913d2bab075f405742d463b0e16219a · Zeichen 8149–8685 im Abschnitt